Venus Remedies Limited (NSE: VENUSREM; BSE: 526953), one of the world’s leading manufacturers of fixed-dosage injectable pharmaceuticals, has received its second incentive disbursement under the Government of India’s Production Linked Incentive (PLI) Scheme for Pharmaceuticals. This disbursement represents 75 percent of the total incentive eligible for FY 2024–25, marking a significant milestone in the company’s PLI journey.
Strong Compliance Drives Continued Eligibility
As per the press release, the incentive follows Venus Remedies’ successful fulfilment of the investment, production, and sales benchmarks mandated under the PLI scheme. Moreover, the company’s continued eligibility and successive disbursements underscore its consistent performance against the programme’s stringent criteria.
As a result, Venus Remedies has demonstrated disciplined execution and a sustained commitment to scaling domestic manufacturing in alignment with national priorities.
Strategic Leverage Under PLI 2.0
As one of the select pharmaceutical companies approved under PLI 2.0, Venus Remedies is well positioned to leverage these incentives to expand manufacturing capacity, adopt advanced technologies, and strengthen its competitive position within India’s evolving pharmaceutical ecosystem.
Furthermore, the support reinforces the company’s long-term focus on innovation-led growth, employment generation, and supply-chain resilience, while contributing meaningfully to the expansion of India’s domestic pharmaceutical manufacturing base.
Leadership Perspective on the Milestone
Commenting on the development, Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, highlighted the broader impact of the incentives.
He stated that the successive PLI disbursements validate the company’s disciplined execution and long-standing commitment to strengthening India’s pharmaceutical manufacturing capabilities. He further noted that the incentives will support capacity expansion, enable investments in globally competitive technologies, and deepen Venus Remedies’ contribution to a resilient and self-reliant healthcare ecosystem. As the company scales responsibly, it remains aligned with national healthcare and industrial priorities, with a strong emphasis on quality, supply-chain security, and long-term value creation.
PLI Scheme: Strengthening India’s Pharmaceutical Manufacturing Base
Launched under the Atmanirbhar Bharat initiative, the Government of India’s PLI Scheme aims to catalyse domestic investment, drive incremental production, and enhance global competitiveness across key manufacturing sectors, including pharmaceuticals.
With a total outlay of ₹15,000 crore spanning FY 2020–21 to FY 2028–29, the scheme has played a pivotal role in strengthening India’s pharmaceutical manufacturing ecosystem and reducing import dependence in critical segments.
Tangible Impact on Trade and Value Addition
Importantly, India has transitioned from being a net importer of bulk drugs to a net exporter. The country moved from a ₹1,930 crore trade deficit in FY 2021–22 to a ₹2,280 crore surplus in FY 2024–25, reflecting the scheme’s impact.
Over the first three years of implementation, pharmaceutical sales under the PLI scheme crossed ₹2.66 lakh crore, including ₹1.70 lakh crore in exports. As of March 2025, domestic value addition reached 83.70 percent, further underscoring the programme’s role in strengthening India’s pharmaceutical self-reliance and global competitiveness.